Fennec Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview

Fennec Pharmaceuticals

03/11/2023 16:37

* Fennec Pharmaceuticals Inc  FENC.OQ   FENC.O  is expected
to show a rise in quarterly revenue when it reports  results 
    * The Research Triangle Park North Carolina-based  company
is
expected to report revenue of $5.337 million, according to the
mean estimate from 6 analysts, based on LSEG data.  
    * ​Refinitiv's mean analyst estimate for Fennec
Pharmaceuticals
Inc is for a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fennec
Pharmaceuticals Inc is $16​, above​ its last closing price
of $6.96. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.17       -0.16      -0.21     Missed  -34.2
 Mar. 31 2023  -0.21       -0.21      -0.23     Missed  -9.6
 Dec. 31 2022  -0.20       -0.26      -0.26     Met     1.8​
 Sep. 30 2022  -0.18       -0.18      -0.31     Missed  -70.6
 ​​Jun.        -0.15       -0.14      -0.19     Missed  -39
 30 2022                                                
 Mar. 31 2022  -0.13       -0.14      -0.14     Met     0​
 Dec. 31 2021  1.14        0.75       -0.18     Missed  -124.1
 Sep. 30 2021  -0.17       -0.17      -0.16     Beat    5.9
 This summary was machine generated November 3 at 16:37 GMT.  All
figures in US dollars  unless otherwise stated